atazanavir sulfate; cobicistat · Bristol · NDA 206353
Evotaz
Earliest generic entry, as listed
6 Oct 2032
Blocked by patent: US 10039718.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10039718 | product | 6 Oct 2032 |
| US 8148374 | substance, product, use U-1279 | 3 Sep 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206353 · 001 · RLD | tablet, oral | EQ 300MG BASE;150MG | 6 Oct 2032 |